Profile data is unavailable for this security.
About the company
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.
- Revenue in GBP (TTM)4.71m
- Net income in GBP-5.51m
- Incorporated2008
- Employees60.00
- LocationScancell Holdings PLCUnit 202 Bellhouse BuildingSanders Road, Oxford Science ParkOXFORD OX4 4GDUnited KingdomGBR
- Phone+44 186 558 2066
- Fax+44 115 823 1863
- Websitehttps://www.scancell.co.uk/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arecor Therapeutics PLC | 5.06m | -8.10m | 27.94m | 37.00 | -- | 9.78 | -- | 5.52 | -0.2208 | -0.2208 | 0.1368 | 0.0756 | 0.6482 | 18.58 | 1.93 | 136,783.80 | -103.79 | -53.69 | -187.88 | -68.26 | -2.45 | -- | -160.13 | -248.39 | 2.00 | -- | 0.0571 | -- | 10.50 | -- | -19.66 | -- | -- | -- |
| ImmuPharma PLC | 0.00 | -3.93m | 31.72m | 6.00 | -- | 93.65 | -- | -- | -0.0089 | -0.0089 | 0.00 | 0.0007 | 0.00 | -- | -- | 0.00 | -139.44 | -89.81 | -259.88 | -121.17 | -- | -- | -- | -9,895.75 | -- | -2.76 | 0.00 | -- | -- | -- | 15.00 | -- | -56.60 | -- |
| Poolbeg Pharma PLC | 0.00 | -5.71m | 32.07m | 10.00 | -- | 2.69 | -- | -- | -0.0114 | -0.0114 | 0.00 | 0.0171 | 0.00 | -- | -- | 0.00 | -45.01 | -- | -46.84 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -47.29 | -- | -- | -- |
| Skinbiotherapeutics PLC | 4.64m | -696.25k | 51.13m | 41.00 | -- | 5.43 | -- | 11.02 | -0.0032 | -0.0032 | 0.0204 | 0.0364 | 0.5349 | 2.80 | 4.81 | 113,125.60 | -8.03 | -44.16 | -9.90 | -53.32 | 61.65 | -- | -15.01 | -175.65 | 4.29 | -12.21 | 0.0954 | -- | 283.74 | -- | 75.79 | -- | 16.61 | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -7.81m | 54.73m | 16.00 | -- | -- | -- | -- | -2.21 | -2.21 | 0.00 | -0.1089 | 0.00 | -- | -- | 0.00 | -169.60 | -87.04 | -210.76 | -102.48 | -- | -- | -- | -- | -- | -2.14 | 1.33 | -- | -- | -- | 16.01 | -- | 2.20 | -- |
| hVIVO PLC | 51.28m | 5.28m | 60.80m | 301.00 | 11.51 | 1.39 | 6.79 | 1.19 | 0.0077 | 0.0077 | 0.0748 | 0.0635 | 0.5914 | -- | 3.32 | 170,362.10 | 6.09 | 5.51 | 9.53 | 10.35 | -- | -- | 10.30 | 6.73 | 1.53 | -- | 0.2521 | 66.99 | 11.92 | 79.44 | -33.90 | -- | 154.59 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.96m | 66.51m | 25.00 | -- | -- | -- | -- | -0.2524 | -0.2524 | 0.00 | -0.1353 | 0.00 | -- | -- | 0.00 | -119.80 | -227.46 | -304.25 | -1,738.54 | -- | -- | -- | -- | -- | -1.65 | 3.64 | -- | -- | -- | 16.24 | -- | 17.71 | -- |
| Bioventix PLC | 13.12m | 7.58m | 91.44m | 16.00 | 12.13 | 7.92 | 11.91 | 6.97 | 1.44 | 1.44 | 2.49 | 2.21 | 0.9864 | 1.84 | 2.10 | 819,741.90 | 57.04 | 58.17 | 64.40 | 64.19 | 90.86 | 92.79 | 57.83 | 61.84 | 8.65 | -- | 0.00 | 105.34 | -3.61 | 4.92 | -6.33 | 1.04 | -43.71 | 11.26 |
| 4Basebio PLC | 1.78m | -14.41m | 91.68m | -- | -- | 4.82 | -- | 51.53 | -0.9923 | -0.9923 | 0.1226 | 1.23 | 0.0729 | 1.54 | 21.56 | -- | -59.05 | -36.81 | -64.81 | -40.98 | 61.55 | 69.88 | -809.95 | -1,160.83 | 11.15 | -95.30 | 0.4485 | -- | 84.39 | 35.80 | -60.90 | -- | 50.57 | -- |
| Scancell Holdings Plc | 4.71m | -5.51m | 129.72m | 60.00 | -- | -- | -- | 27.54 | -0.0053 | -0.0053 | 0.0047 | -0.0081 | 0.2946 | -- | 8.26 | 78,516.66 | -34.46 | -33.29 | -- | -44.23 | 94.95 | -- | -116.98 | -502.03 | -- | -- | 2.07 | -- | -- | -- | -109.46 | -- | 124.48 | -- |
| Avacta Group Plc | -11.09m | -33.09m | 262.05m | 151.00 | -- | 1,626.71 | -- | -- | -0.0891 | -0.1579 | -0.0298 | 0.0004 | -0.1872 | -- | -- | -73,456.95 | -55.83 | -43.48 | -129.38 | -78.27 | -- | 63.54 | -- | -781.44 | 0.7883 | -0.4837 | 0.993 | -- | -96.04 | -- | -0.9503 | -- | -- | -- |
| Puretech Health PLC | 4.69m | 37.19m | 312.11m | 56.00 | 8.49 | 1.12 | 12.04 | 66.54 | 0.1521 | 0.1521 | 0.0195 | 1.15 | 0.0113 | -- | 2.81 | 83,760.91 | 5.63 | -3.27 | 6.57 | -3.83 | -- | -- | 498.87 | -253.25 | -- | -- | 0.0537 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 08 Sep 2025 | 297.19m | 28.64% |
| Vulpes Investment Management Pte Ltd.as of 12 Sep 2025 | 143.54m | 13.83% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2025 | 12.77m | 1.23% |
